Par (NYSE: PRX) has been developing, manufacturing and distributing generic pharmaceuticals since 1978. Today, the company’s sales place it  among the top 10 largest generic pharmaceutical companies in the U.S.

In 2007, Par launched five new products and filed ANDAs on nine more. It currently has 45 ANDAs pending approval, making it one of the most promising pipelines in the generics industry. Our goal is to continue the growth that propelled Par into the top echelon of generic drug companies, and simultaneously move forward with the development of a line of branded supportive care therapies for AIDS and cancer patients.

To that end, Par has taken aggressive steps to expand its proprietary products portfolio. Since June 2007, the company's proprietary products division, Strativa Phamaceuticals has in-licensed four branded products in development -- Zensana™ (ondansetron HCl) Oral Spray, Loramyc™ (miconazole Lauriad^®), ONCONASE^®, and an oral thin film formulation of ondansetron.

Par has one of the most promising new product pipelines in the generic drug industry, with 45 products awaiting FDA approval, including as many as 17 first-to-files, and more than 30 others in development. In recent years, the company introduced generic versions of several major pharmaceutical products, including Inderal^® LA, TOPROL XL^®, Flonase^®, Dostinex^®, Ultracet^®, Accupril^®, Paxil^®, Prozac^®, Marinol^® and Imitrex^®.